Late Stage Lung Cancer
Late Stage Lung Cancer
批准号:
8340005
负责人:
ROBERT Alan FIGLIN
金额:
$53.35万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2014-08-31
关键词:
AccountingActivities of Daily LivingAdvanced Practice NurseAgeAnxietyBody Weight decreasedCancer PatientCaregiversCaringCause of DeathCharacteristicsCognitionComorbidityDataDiagnosisDietitianDiseaseDistressEmotionalEnrollmentEthnic OriginFamilyFamily CaregiverGenderGeriatric AssessmentGoalsHealthcareHospitalsIndividualInstructionInterventionKarnofsky Performance StatusLinkMalignant NeoplasmsMalignant neoplasm of lungMeasuresMemoryMental DepressionMeta-AnalysisMethodsModelingNon-Small-Cell Lung CarcinomaNutritional statusOutcomePalliative CarePatientsPerformancePhasePopulationPsychologistPublic HealthQuality of lifeResearchResearch PersonnelSeaServicesSocial WorkSocial supportStagingStructureSubgroupSupportive careSymptomsSystemTestingTimeTreatment FactorUnited StatesUnresectableVisitWorkbasecancer carecancer palliative treatmentcaregivingcostdesignfallsfunctional statusgroup interventionimprovedinstrumental activity of daily livinginterdisciplinary collaborationolder patientphysical conditioningprimary outcomeprogramsprospectivepsychoeducational interventionpsychological distresspsychosocialsatisfactionsocialsymptom managementtreatment as usual
中文摘要
项目概述(航海说明):
英文摘要
PROJECT SUMMARY (Sea instructions):
Project 2: Late Stage Lung Cancer focuses on Stages Illb-IV unresectable lung cancer within a program project with central themes related to palliative care, quality of life (QOL), and symptom management. This project focuses on Late Stage Lung Cancer, a population who have decreased survival and high QOL and symptom concerns. The aims of the research are:
Aim1: Test the effects of the Palliative Care Intervention (PCI) on overall QOL and psychological distress for patients with Late (Stage Illb-IV) non-resectable NSCLC compared to a group receiving usual care.
Aim 2: Compare symptom control in the PCI group versus the usual care group in Late Stage NSCLC.
Aim 3: Compare geriatric assessment outcomes (OARS Instrumental Activities of Daily Living, MOS Activities of Daily Living, MOS Social Activities Limitation Scale, Hospital Anxiety and Depression Scale scores, and the Karnofsky Performance Scale) in the PCI group versus the usual care group.
Aim 4: Test the effects of the PCI on resource use as compared to the usual care group.
Aim 5: Identify subgroups of patients who benefit most from the PCI in relation to sociodemographic characteristics, treatment factors, and geriatric assessment predictors at the 12 week primary end point.
A two-group, prospective sequential, quasi-experimental, tandem enrollment design (N=326) will be used for this project, in which the usual care group is accrued and followed during Phase 1 and the intervention group is accrued and followed during Phase 2.
The proposed PCI intervention combines pre-treatment assessment and goal setting through the collaboration of an interdisciplinary team. The Palliative Care Intervention is based on pilot work completed from 2005-2007 by the investigators documenting needs of lung cancer patients and testing the intervention.
This project has great significance to public health given the significant numbers of people diagnosed with lung cancer and the associated individual and societal costs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cancer Center Support Grant
-
批准号:7931158
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2009
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
Phase II Trial of Recombinant Human Granulocyte Macrop
-
批准号:7043101
-
项目类别:
-
资助金额:$1.09万
-
财政年份:2003
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
CORE--CLINICAL RESEARCH UNIT
-
批准号:6563717
-
项目类别:
-
资助金额:$16.72万
-
财政年份:2001
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
CORE--CLINICAL RESEARCH UNIT
-
批准号:6412898
-
项目类别:
-
资助金额:$16.72万
-
财政年份:2000
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF AND RHU IL4 TO TREAT CANCER
-
批准号:6412126
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2000
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
ANTIGEN SPECIFIC IMMUNOTHERAPY IN MUC 1 POSITIVE PATIENTS
-
批准号:6412107
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2000
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
CORE--CLINICAL RESEARCH UNIT
-
批准号:6300043
-
项目类别:
-
资助金额:$23.79万
-
财政年份:1999
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
ANTIGEN SPECIFIC IMMUNOTHERAPY IN MUC 1 POSITIVE PATIENTS
-
批准号:6452009
-
项目类别:
-
资助金额:$20.73万
-
财政年份:1999
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF AND RHU IL4 TO TREAT CANCER
-
批准号:6452020
-
项目类别:
-
资助金额:$20.73万
-
财政年份:1999
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
CORE--CLINICAL RESEARCH UNIT
-
批准号:6101702
-
项目类别:
-
资助金额:$23.79万
-
财政年份:1998
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF AND RHU IL4 TO TREAT CANCER
-
批准号:6118445
-
项目类别:
-
资助金额:$0.19万
-
财政年份:1998
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF AND RHU IL4 TO TREAT CANCER
-
批准号:6297754
-
项目类别:
-
资助金额:$0.19万
-
财政年份:1998
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
ANTIGEN SPECIFIC IMMUNOTHERAPY IN MUC 1 POSITIVE PATIENTS
-
批准号:6297735
-
项目类别:
-
资助金额:$0.19万
-
财政年份:1998
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
CORE--CLINICAL RESEARCH UNIT
-
批准号:6268835
-
项目类别:
-
资助金额:$24.06万
-
财政年份:1998
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
ANTIGEN SPECIFIC IMMUNOTHERAPY IN MUC 1 POSITIVE PATIENTS
-
批准号:6265336
-
项目类别:
-
资助金额:$0.19万
-
财政年份:1998
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
Cancer Center Support Grant
-
批准号:7682635
-
项目类别:
-
资助金额:$9.51万
-
财政年份:1997
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
RANDOMIZED STUDY OF PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH
-
批准号:6249571
-
项目类别:
-
资助金额:$1.8万
-
财政年份:1997
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
PHASE I TRIAL TO DETERMINE THE SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF
-
批准号:6279640
-
项目类别:
-
资助金额:$1.77万
-
财政年份:1997
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
Cancer Center Support Grant
-
批准号:7928387
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1997
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
Cancer Center Support Grant
-
批准号:7754478
-
项目类别:
-
资助金额:$9.48万
-
财政年份:1997
-
负责人:ROBERT Alan FIGLIN
-
依托单位:
海外基金